United Therapeutics Co. (NASDAQ:UTHR) Shares Acquired by Wedge Capital Management L L P NC

Wedge Capital Management L L P NC boosted its holdings in United Therapeutics Co. (NASDAQ:UTHR) by 35.0% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 107,276 shares of the biotechnology company’s stock after purchasing an additional 27,829 shares during the quarter. Wedge Capital Management L L P NC owned about 0.24% of United Therapeutics worth $33,070,000 at the end of the most recent quarter.

A number of other large investors have also recently bought and sold shares of UTHR. Newbridge Financial Services Group Inc. purchased a new stake in shares of United Therapeutics in the fourth quarter valued at about $25,000. Dunhill Financial LLC increased its position in United Therapeutics by 100.0% in the 4th quarter. Dunhill Financial LLC now owns 100 shares of the biotechnology company’s stock valued at $35,000 after acquiring an additional 50 shares during the period. State of Wyoming acquired a new position in United Therapeutics in the 4th quarter valued at about $62,000. Curat Global LLC purchased a new stake in United Therapeutics during the 1st quarter valued at approximately $63,000. Finally, Millstone Evans Group LLC purchased a new stake in United Therapeutics during the 4th quarter valued at approximately $67,000. Institutional investors and hedge funds own 94.08% of the company’s stock.

Insider Buying and Selling

In other United Therapeutics news, EVP Paul A. Mahon sold 11,000 shares of United Therapeutics stock in a transaction dated Thursday, April 3rd. The shares were sold at an average price of $306.18, for a total transaction of $3,367,980.00. Following the completion of the transaction, the executive vice president now owns 36,781 shares in the company, valued at approximately $11,261,606.58. The trade was a 23.02% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Tommy G. Thompson sold 2,500 shares of the company’s stock in a transaction dated Monday, March 24th. The shares were sold at an average price of $318.80, for a total transaction of $797,000.00. Following the completion of the sale, the director now directly owns 8,480 shares in the company, valued at $2,703,424. This trade represents a 22.77% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 56,500 shares of company stock worth $16,923,950 in the last quarter. Company insiders own 10.30% of the company’s stock.

United Therapeutics Stock Up 1.9%

Shares of UTHR opened at $325.82 on Friday. The company has a market capitalization of $14.70 billion, a PE ratio of 14.31, a P/E/G ratio of 0.97 and a beta of 0.57. United Therapeutics Co. has a 52-week low of $266.98 and a 52-week high of $417.82. The company has a 50-day simple moving average of $301.06 and a 200-day simple moving average of $333.37.

United Therapeutics (NASDAQ:UTHR) last issued its earnings results on Wednesday, April 30th. The biotechnology company reported $6.63 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.29 by $0.34. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. The company had revenue of $794.40 million during the quarter, compared to analysts’ expectations of $726.82 million. During the same period last year, the company posted $6.17 earnings per share. The firm’s quarterly revenue was up 17.2% compared to the same quarter last year. On average, research analysts anticipate that United Therapeutics Co. will post 24.48 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research firms have recently issued reports on UTHR. Morgan Stanley boosted their target price on United Therapeutics from $346.00 to $348.00 and gave the company an “equal weight” rating in a report on Thursday, May 1st. Bank of America upgraded shares of United Therapeutics from an “underperform” rating to a “neutral” rating and set a $314.00 price objective on the stock in a research report on Monday, April 21st. JPMorgan Chase & Co. cut their price objective on shares of United Therapeutics from $355.00 to $350.00 and set an “overweight” rating for the company in a research report on Thursday, May 1st. Cantor Fitzgerald started coverage on shares of United Therapeutics in a research note on Monday, June 2nd. They issued an “overweight” rating and a $405.00 target price for the company. Finally, HC Wainwright reiterated a “buy” rating and set a $425.00 price target on shares of United Therapeutics in a research note on Monday, May 5th. Four research analysts have rated the stock with a hold rating and ten have given a buy rating to the company. Based on data from MarketBeat.com, United Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $393.00.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.